- Home
- FWRG vs CDNA Comparison
FWRG vs CDNA Comparison
Compare FWRG & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FWRG | CDNA |
|---|---|---|
| Founded | 1983 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 941.7M | 1.0B |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | FWRG | CDNA |
|---|---|---|
| Price | $16.03 | $20.63 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 7 |
| Target Price | $21.56 | ★ $26.67 |
| AVG Volume (30 Days) | ★ 1.3M | 738.6K |
| Earning Date | 03-10-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.08 | ★ 1.22 |
| Revenue | ★ $1,169,440,000.00 | $357,998,000.00 |
| Revenue This Year | $22.16 | $14.47 |
| Revenue Next Year | $15.95 | $11.35 |
| P/E Ratio | $201.75 | ★ $17.12 |
| Revenue Growth | ★ 17.27 | 14.46 |
| 52 Week Low | $12.90 | $10.96 |
| 52 Week High | $22.71 | $25.55 |
Technical Indicators
Market Signals| Indicator | FWRG | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 45.97 | 56.01 |
| Support Level | $16.09 | $20.09 |
| Resistance Level | $17.14 | $21.09 |
| Average True Range (ATR) | 0.57 | 1.06 |
| MACD | 0.04 | 0.05 |
| Stochastic Oscillator | 43.93 | 77.67 |
Price Performance
Historical ComparisonAbout FWRG First Watch Restaurant Group Inc.
First Watch Restaurant Group Inc is a daytime restaurant concept serving made-to-order breakfast, brunch, and lunch using fresh ingredients. It generates revenues from Restaurant sales and Franchise revenues.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.